Available Technologies

Browse Penn-owned technologies available for licensing.


Search Results - mark greene

6 Results Sort By:
Antibody-like therapeutic platform with effector function
Technology Overview: While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibodies require post-translational modifications and...
Published: 3/18/2020   |   Inventor(s): Mark Greene
Keywords(s): Antibody
Category(s): Therapeutics & Vaccines
Diagnosis and treatment of prostate cancer using a prostate cancer antibody
Monoclonal antibody and immunotherapy use in prostate cancer Technology Overview: Both androgen dependent and independent prostatic carcinomas have a high potential to metastasize. Unfortunately, the overall 5-year survival rate for metastatic prostate cancer is only 34%. Dr. Greene and his collaborators at the University of Pennsylvania have...
Published: 3/16/2020   |   Inventor(s): Mark Greene
Keywords(s): Oncology
Category(s): Diagnostics, Therapeutics & Vaccines
Her2/Neu Inhibitors for Cancer Therapy and Molecular Imaging
Cancer affects approximately 10 million people globally, with breast and lung cancer accounting for 25% of cancer incidences. Assuming over expression of Her2 is responsible for 25% of the breast cancer and lung cancer, and then the estimated market is about one million. The estimated price of Lapatinib, a small molecule tyrosine kinase inhibitor,...
Published: 3/16/2020   |   Inventor(s): Mark Greene
Keywords(s): Oncology
Category(s): Therapeutics & Vaccines, Imaging
Therapy for heparin-induced thrombocytopenia (HIT) targeting the epitope structure of the disease –inducing antibody
Technology Overview: Roughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis and thrombocytopenia. The Greene lab has identified...
Published: 1/23/2020   |   Inventor(s): Mark Greene
Keywords(s): Antibody
Category(s): Therapeutics & Vaccines, Diagnostics, Research Tools & Reagents
TIP60 inhibitors – therapy for Irritable Bowel Disease (IBD); ulcerative colitis and Crohn’s diseases
Inhibitors of TIP60, maintaining regulatory T cells (Tregs) and ameliorating autoimmune diseases. Problem: Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of digestive tract. IBD includes ulcerative colitis and Crohn’s disease both very prevalent and known to cause severe complications and discomfort. Inhibitors...
Published: 12/4/2018   |   Inventor(s): Mark Greene
Category(s): Therapeutics & Vaccines
A method to identify modulators for regulatory T cell functions
Technology Overview: Maintenance of tolerance to self-antigens is essential for the prevention of autoimmunity. This process is known to involve specific regulatory T cells (Treg) and the expression of the forkhead family transcription factor, FOXP3. FOXP3 is a “sufficient” regulator of the development and function of peripheral Treg...
Published: 8/10/2017   |   Inventor(s): Mark Greene
Keywords(s): Autoimmune
Category(s): Research Tools & Reagents